Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.

导出 OA

翻译打印收藏纠错

作者： Bastiaan M,Privé ^[1] ; Marcel J R,Janssen ^[1] ; Inge M,van Oort ^[2] ; Constantijn H J,Muselaers ^[2] ; Marianne A,Jonker ^[3] ; Michel,de Groot ^[1] ; Niven,Mehra ^[4] ; J Fred,Verzijlbergen ^[1] ; Tom W J,Scheenen ^[1] ; Patrik,Zámecnik ^[1] ; Jelle O,Barentsz ^[1] ; Martin,Gotthardt ^[1] ; Walter,Noordzij ^[5] ; Wouter V,Vogel ^[6] ; Andries M,Bergman ^[7] ; Henk G,van der Poel ^[8] ; André N,Vis ^[9] ; Daniela E,Oprea-Lager ^[10] ; Winald R,Gerritsen ^[11] ; J Alfred,Witjes ^[4] ; James,Nagarajah ^[2]

作者单位： Department of Radiology and Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, 6525, GA, Nijmegen, The Netherlands. ^[1] Department of Urology, Radboudumc, Nijmegen, The Netherlands. ^[2] Department of Health Evidence, Radboudumc, Nijmegen, The Netherlands. ^[3] Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands. ^[4] Department of Radiology and Nuclear Medicine, University Medical Center Groningen, Groningen, The Netherlands. ^[5] Department of Radiology and Nuclear Medicine, NKI Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ^[6] Department of Radiation Oncology, NKI Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ^[7] Department of Medical Oncology, NKI Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ^[8] Department of Urology, NKI Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ^[9] Department of Urology, Amsterdam University Medical Center, Amsterdam, The Netherlands. ^[10] Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands. ^[11] Department of Radiology and Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, 6525, GA, Nijmegen, The Netherlands. james.nagarajah@radboudumc.nl. ^[12]

关键词 Hormone sensitive prostate Cancer Lutetium-177-PSMA Metastases directed therapy Oligometastases Radioligand therapy Urologic oncology